917 related articles for article (PubMed ID: 19012492)
1. Postexposure immunization with modified vaccinia virus Ankara or conventional Lister vaccine provides solid protection in a murine model of human smallpox.
Paran N; Suezer Y; Lustig S; Israely T; Schwantes A; Melamed S; Katz L; Preuss T; Hanschmann KM; Kalinke U; Erez N; Levin R; Velan B; Löwer J; Shafferman A; Sutter G
J Infect Dis; 2009 Jan; 199(1):39-48. PubMed ID: 19012492
[TBL] [Abstract][Full Text] [Related]
2. Enhanced immunogenicity and protective effect conferred by vaccination with combinations of modified vaccinia virus Ankara and licensed smallpox vaccine Dryvax in a mouse model.
Meseda CA; Garcia AD; Kumar A; Mayer AE; Manischewitz J; King LR; Golding H; Merchlinsky M; Weir JP
Virology; 2005 Sep; 339(2):164-75. PubMed ID: 15993917
[TBL] [Abstract][Full Text] [Related]
3. Comparative efficacy of modified vaccinia Ankara (MVA) as a potential replacement smallpox vaccine.
Phelps AL; Gates AJ; Hillier M; Eastaugh L; Ulaeto DO
Vaccine; 2007 Jan; 25(1):34-42. PubMed ID: 16950548
[TBL] [Abstract][Full Text] [Related]
4. Protection induced in mice against a lethal orthopox virus by the Lister strain of vaccinia virus and modified vaccinia virus Ankara (MVA).
Abdalrhman I; Gurt I; Katz E
Vaccine; 2006 May; 24(19):4152-60. PubMed ID: 16603280
[TBL] [Abstract][Full Text] [Related]
5. Vaccinia virus-induced smallpox postvaccinal encephalitis in case of blood-brain barrier damage.
Garcel A; Fauquette W; Dehouck MP; Crance JM; Favier AL
Vaccine; 2012 Feb; 30(7):1397-405. PubMed ID: 22227123
[TBL] [Abstract][Full Text] [Related]
6. Effective post-exposure protection against lethal orthopoxviruses infection by vaccinia immune globulin involves induction of adaptive immune response.
Lustig S; Maik-Rachline G; Paran N; Melamed S; Israely T; Erez N; Orr N; Reuveny S; Ordentlich A; Laub O; Shafferman A; Velan B
Vaccine; 2009 Mar; 27(11):1691-9. PubMed ID: 19195492
[TBL] [Abstract][Full Text] [Related]
7. E3L and F1L Gene Functions Modulate the Protective Capacity of Modified Vaccinia Virus Ankara Immunization in Murine Model of Human Smallpox.
Volz A; Jany S; Freudenstein A; Lantermann M; Ludwig H; Sutter G
Viruses; 2018 Jan; 10(1):. PubMed ID: 29300297
[TBL] [Abstract][Full Text] [Related]
8. The nonreplicating smallpox candidate vaccines defective vaccinia Lister (dVV-L) and modified vaccinia Ankara (MVA) elicit robust long-term protection.
Coulibaly S; Brühl P; Mayrhofer J; Schmid K; Gerencer M; Falkner FG
Virology; 2005 Oct; 341(1):91-101. PubMed ID: 16061267
[TBL] [Abstract][Full Text] [Related]
9. Identification of vaccinia virus epitope-specific HLA-A*0201-restricted T cells and comparative analysis of smallpox vaccines.
Drexler I; Staib C; Kastenmuller W; Stevanović S; Schmidt B; Lemonnier FA; Rammensee HG; Busch DH; Bernhard H; Erfle V; Sutter G
Proc Natl Acad Sci U S A; 2003 Jan; 100(1):217-22. PubMed ID: 12518065
[TBL] [Abstract][Full Text] [Related]
10. Safety, immunogenicity and protective efficacy in mice of a new cell-cultured Lister smallpox vaccine candidate.
Ferrier-Rembert A; Drillien R; Meignier B; Garin D; Crance JM
Vaccine; 2007 Nov; 25(49):8290-7. PubMed ID: 17964011
[TBL] [Abstract][Full Text] [Related]
11. TLR3 and TLR9 agonists improve postexposure vaccination efficacy of live smallpox vaccines.
Israely T; Melamed S; Achdout H; Erez N; Politi B; Waner T; Lustig S; Paran N
PLoS One; 2014; 9(10):e110545. PubMed ID: 25350003
[TBL] [Abstract][Full Text] [Related]
12. Substitution of vaccinia virus Elstree by modified vaccinia virus Ankara to test the virucidal efficacy of chemical disinfectants.
Hartnack S; Essbauer S; Truyen U
Zoonoses Public Health; 2008; 55(2):99-105. PubMed ID: 18234028
[TBL] [Abstract][Full Text] [Related]
13. Phenotypic and genetic diversity of the traditional Lister smallpox vaccine.
Garcel A; Perino J; Crance JM; Drillien R; Garin D; Favier AL
Vaccine; 2009 Jan; 27(5):708-17. PubMed ID: 19059294
[TBL] [Abstract][Full Text] [Related]
14. Highly attenuated smallpox vaccine protects mice with and without immune deficiencies against pathogenic vaccinia virus challenge.
Wyatt LS; Earl PL; Eller LA; Moss B
Proc Natl Acad Sci U S A; 2004 Mar; 101(13):4590-5. PubMed ID: 15070762
[TBL] [Abstract][Full Text] [Related]
15. Modified vaccinia virus Ankara immunization protects against lethal challenge with recombinant vaccinia virus expressing murine interleukin-4.
McCurdy LH; Rutigliano JA; Johnson TR; Chen M; Graham BS
J Virol; 2004 Nov; 78(22):12471-9. PubMed ID: 15507634
[TBL] [Abstract][Full Text] [Related]
16. Development of eczema vaccinatum in atopic mouse models and efficacy of MVA vaccination against lethal poxviral infection.
Knitlova J; Hajkova V; Voska L; Elsterova J; Obrova B; Melkova Z
PLoS One; 2014; 9(12):e114374. PubMed ID: 25486419
[TBL] [Abstract][Full Text] [Related]
17. The Virulence of Different Vaccinia Virus Strains Is Directly Proportional to Their Ability To Downmodulate Specific Cell-Mediated Immune Compartments
de Freitas LFD; Oliveira RP; Miranda MCG; Rocha RP; Barbosa-Stancioli EF; Faria AMC; da Fonseca FG
J Virol; 2019 Mar; 93(6):. PubMed ID: 30567985
[TBL] [Abstract][Full Text] [Related]
18. Rapid expansion of CD8+ T cells in wild-type and type I interferon receptor-deficient mice correlates with protection after low-dose emergency immunization with modified vaccinia virus Ankara.
Volz A; Langenmayer M; Jany S; Kalinke U; Sutter G
J Virol; 2014 Sep; 88(18):10946-57. PubMed ID: 25008931
[TBL] [Abstract][Full Text] [Related]
19. Modified vaccinia Ankara: potential as an alternative smallpox vaccine.
McCurdy LH; Larkin BD; Martin JE; Graham BS
Clin Infect Dis; 2004 Jun; 38(12):1749-53. PubMed ID: 15227622
[TBL] [Abstract][Full Text] [Related]
20. Induction of human T cell-mediated immune responses after primary and secondary smallpox vaccination.
Kennedy JS; Frey SE; Yan L; Rothman AL; Cruz J; Newman FK; Orphin L; Belshe RB; Ennis FA
J Infect Dis; 2004 Oct; 190(7):1286-94. PubMed ID: 15346340
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]